Healthy
Conditions
Brief summary
The main purpose of this study is to assess and compare a single capsule and multiple capsules of Orforglipron based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants under fasted and fed conditions. How the body handles and eliminates the study drug after meals and on an empty stomach will be measured. Information about any adverse effects experienced will be collected and the safety and tolerability of Orforglipron will also be evaluated. The study will last approximately 21 weeks, including a screening period.
Interventions
DRUGOrforglipron
Administered orally
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Have a stable body weight, that is, less than a 5% body weight change, for 1 month prior to randomization and body mass index (BMI) within the range 23.0 to 35.0 kilogram per square meter (kg/m²), inclusive * Have safety laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator * Have venous access sufficient to allow for blood sampling * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Exclusion criteria
* Have a hemoglobin A1c (HbA1c) test level greater than or equal to 6.5% * Have an estimated glomerular filtration rate less than 30 milliliter per minute per 1.73 square meter (mL/min/1.73m²) * Have a history of significant active or unstable major depressive disorder or other severe psychiatric disorder, for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder within the 2 years prior to screening * Actively suicidal and therefore deemed to be at significant risk for suicide * Have a known clinically significant gastric emptying abnormality * Have history or presence of acute or chronic pancreatitis or an elevation in serum lipase or amylase levels greater than 3 times the upper limit of normal (ULN) * Have an abnormal blood pressure (BP), pulse rate, or both * Have difficulty swallowing capsules
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PK: Steady-state Maximum Concentration (Cmax) of Orforglipron (Fasted State) | Week 3 Through Week 16 | PK: Steady-state Cmax of Orforglipron (Fasted State) |
| Pharmacokinetics (PK): Steady-state Area Under the Concentration Versus Time Curve (AUC) of Orforglipron (Fasted State) | Week 3 Through Week 16 | PK: Steady-state AUC of Orforglipron (Fasted State) |
| PK: Steady-state AUC of Orforglipron (Fed State) | Week 3 Through Week 16 | PK: Steady-state AUC of Orforglipron (Fed State) |
| PK: Steady-state Cmax of Orforglipron (Fed State) | Week 3 Through Week 16 | PK: Steady-state Cmax of Orforglipron (Fed State) |
Countries
Japan
Outcome results
None listed